CN105712977B - 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物 - Google Patents

作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物 Download PDF

Info

Publication number
CN105712977B
CN105712977B CN201610094782.9A CN201610094782A CN105712977B CN 105712977 B CN105712977 B CN 105712977B CN 201610094782 A CN201610094782 A CN 201610094782A CN 105712977 B CN105712977 B CN 105712977B
Authority
CN
China
Prior art keywords
disorders
diazepan
disorder
compounds
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201610094782.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105712977A (zh
Inventor
M.A.莱塔维克
E.M.斯托金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40297867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105712977(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN105712977A publication Critical patent/CN105712977A/zh
Application granted granted Critical
Publication of CN105712977B publication Critical patent/CN105712977B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201610094782.9A 2007-11-20 2008-11-17 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物 Expired - Fee Related CN105712977B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98924607P 2007-11-20 2007-11-20
US60/989246 2007-11-20
CN200880117055A CN101868454A (zh) 2007-11-20 2008-11-17 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880117055A Division CN101868454A (zh) 2007-11-20 2008-11-17 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物

Publications (2)

Publication Number Publication Date
CN105712977A CN105712977A (zh) 2016-06-29
CN105712977B true CN105712977B (zh) 2021-06-29

Family

ID=40297867

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610094782.9A Expired - Fee Related CN105712977B (zh) 2007-11-20 2008-11-17 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物
CN200880117055A Pending CN101868454A (zh) 2007-11-20 2008-11-17 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880117055A Pending CN101868454A (zh) 2007-11-20 2008-11-17 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物

Country Status (22)

Country Link
US (1) US8883776B2 (cg-RX-API-DMAC7.html)
EP (1) EP2222664B1 (cg-RX-API-DMAC7.html)
JP (1) JP5498390B2 (cg-RX-API-DMAC7.html)
KR (1) KR101546712B1 (cg-RX-API-DMAC7.html)
CN (2) CN105712977B (cg-RX-API-DMAC7.html)
AR (2) AR069387A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008326561B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820481A2 (cg-RX-API-DMAC7.html)
CA (1) CA2706328C (cg-RX-API-DMAC7.html)
CL (1) CL2008003465A1 (cg-RX-API-DMAC7.html)
CO (1) CO6210700A2 (cg-RX-API-DMAC7.html)
CR (1) CR11529A (cg-RX-API-DMAC7.html)
EA (1) EA018582B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010190A (cg-RX-API-DMAC7.html)
MX (1) MX2010005488A (cg-RX-API-DMAC7.html)
MY (1) MY158253A (cg-RX-API-DMAC7.html)
NI (1) NI201000086A (cg-RX-API-DMAC7.html)
NZ (1) NZ584998A (cg-RX-API-DMAC7.html)
TW (1) TWI491604B (cg-RX-API-DMAC7.html)
UA (1) UA103468C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009067401A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201004334B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
WO2009030716A1 (en) * 2007-09-06 2009-03-12 Glaxo Group Limited Piperazine derivative having affinity for the histamine h3 receptor
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
CA2721303C (en) * 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
HRP20170776T1 (hr) 2009-03-18 2017-08-11 Janssen Pharmaceutica N.V. Postupak za pripravu modulatora histaminskog h3 receptora
CA2774981A1 (en) * 2009-09-21 2011-03-24 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040144A1 (en) * 2003-10-15 2005-05-06 Glaxo Group Limited Novel compounds
US20070167435A1 (en) * 2005-12-21 2007-07-19 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
WO2007143422A2 (en) * 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE817911C (de) 1947-12-16 1951-10-22 Chem Fab Tempelhof Preuss & Te Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden
BE726551A (cg-RX-API-DMAC7.html) 1968-01-22 1969-06-16
ES436109A1 (es) 1974-04-04 1977-01-01 Christiaens Sa A Procedimiento para la preparacion de nuevos derivados de pi-ridina.
DE3366369D1 (en) 1982-03-17 1986-10-30 Smith Kline French Lab Pyridine derivatives
GB8311443D0 (en) 1983-04-27 1983-06-02 Smith Kline French Lab Chemical compounds
GB8320505D0 (en) 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
GB8332091D0 (en) 1983-12-01 1984-01-11 Smith Kline French Lab Chemical compounds
JPS61149119A (ja) 1984-12-22 1986-07-07 旭光学工業株式会社 検眼用試験枠
US4792547A (en) 1985-12-26 1988-12-20 Hokuriku Pharmaceutical Co., Ltd. Pyrazine-2-carboxamide derivatives useful in treating allergic disease
JPH0637595B2 (ja) 1986-08-06 1994-05-18 日本ペイント株式会社 陰極電着塗料組成物
GB9025828D0 (en) 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
JP3354271B2 (ja) 1993-02-25 2002-12-09 三共株式会社 ピリジルオキシアミド誘導体
DE69628705T2 (de) 1995-08-24 2004-05-13 Basf Ag Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
EP0881217A4 (en) 1995-12-28 2000-01-26 Kureha Chemical Ind Co Ltd METHOD FOR PRODUCING PYRIDINE CARBOXAMIDES AND THIOCARBOXAMIDES
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
CA2374898C (en) 1999-05-21 2009-12-08 Biovitrum Ab Pyrazinyl-piperazine compounds, their use and preparation
US6399607B1 (en) 1999-07-02 2002-06-04 Research Foundation-State University Of New York Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin
DE10023492A1 (de) 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP2002322163A (ja) 2001-04-20 2002-11-08 Sumitomo Pharmaceut Co Ltd ピペラジン誘導体
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
KR20040010713A (ko) 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
AU2002363174B2 (en) 2001-11-01 2008-09-25 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
PL372390A1 (en) 2002-02-05 2005-07-25 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
GB0206219D0 (en) 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
JP2006512404A (ja) * 2002-10-22 2006-04-13 グラクソ グループ リミテッド H3受容体リガンドとしてのアリールオキシアルキルアミン誘導体
ATE449766T1 (de) 2002-10-23 2009-12-15 Janssen Pharmaceutica Nv Piperazinyl- und diazapanylbenzamide und- benzothioamide
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7595316B2 (en) 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
MXPA06001053A (es) 2003-07-29 2006-04-11 Novo Nordisk As Piridazinil-piperazinas y su uso como ligandos del receptor de histamina h3.
WO2005023247A1 (en) 2003-09-03 2005-03-17 Smithkline Beecham Corporation Compounds and methods
MXPA06011410A (es) 2004-03-31 2007-04-20 Johnson & Johnson Compuestos heterociclicos sin imidazol como moduladores de receptor de histamina h3.
JP2007531753A (ja) * 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR101336106B1 (ko) 2005-09-16 2013-12-05 얀센 파마슈티카 엔.브이. 히스타민 h3 수용체의 조절제로서 사이클로프로필 아민
AU2006331850A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
WO2007108936A2 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CN101511807A (zh) * 2006-06-29 2009-08-19 詹森药业有限公司 组胺h3受体的取代的苯甲酰胺调节剂
WO2009067406A1 (en) * 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040144A1 (en) * 2003-10-15 2005-05-06 Glaxo Group Limited Novel compounds
US20070167435A1 (en) * 2005-12-21 2007-07-19 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
WO2007143422A2 (en) * 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
ZA201004334B (en) 2011-10-26
MX2010005488A (es) 2010-06-01
CA2706328A1 (en) 2009-05-28
CN101868454A (zh) 2010-10-20
US8883776B2 (en) 2014-11-11
WO2009067401A1 (en) 2009-05-28
EA201070637A1 (ru) 2010-12-30
KR20100098636A (ko) 2010-09-08
US20090131415A1 (en) 2009-05-21
ECSP10010190A (es) 2010-06-29
AU2008326561B2 (en) 2013-12-05
HK1147994A1 (en) 2011-08-26
KR101546712B1 (ko) 2015-08-24
BRPI0820481A2 (pt) 2015-06-16
CN105712977A (zh) 2016-06-29
UA103468C2 (ru) 2013-10-25
CR11529A (es) 2012-10-25
NZ584998A (en) 2012-08-31
CL2008003465A1 (es) 2009-03-06
AU2008326561A1 (en) 2009-05-28
EA018582B1 (ru) 2013-09-30
NI201000086A (es) 2011-03-17
JP5498390B2 (ja) 2014-05-21
TW200936579A (en) 2009-09-01
AR110977A2 (es) 2019-05-22
CO6210700A2 (es) 2010-10-20
JP2011503233A (ja) 2011-01-27
AR069387A1 (es) 2010-01-20
EP2222664A1 (en) 2010-09-01
EP2222664B1 (en) 2014-10-29
MY158253A (en) 2016-09-30
TWI491604B (zh) 2015-07-11
CA2706328C (en) 2016-04-19

Similar Documents

Publication Publication Date Title
AU2023202086B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
KR101921404B1 (ko) 신규 2치환 1,2,4-트리아진 화합물
CN101495456B (zh) 作为组胺h3受体的调节剂的取代的吡啶基酰胺化合物
EA039808B1 (ru) Аминотриазолопиридины в качестве ингибиторов киназ
MX2011000460A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3.
KR20090033885A (ko) N-(아미노헤테로아릴)-1h-인돌-2-카르복스아미드 유도체,및 그의 제조법 및 치료 용도
EP3416639A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
AU2019293235A1 (en) Immunomodulatory compounds
JP5498390B2 (ja) ヒスタミンh3受容体のモジュレーターとしてのシクロアルキルオキシ−及びヘテロシクロアルキルオキシピリジン化合物
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
KR102756903B1 (ko) 헤테로시클릭 화합물
CA3085874A1 (en) Substituted pyrrolidine amides i
JP5642149B2 (ja) ヒスタミンh3受容体モジュレーターの調製プロセス
CN121794269A (zh) 含二氢嘧啶-2,4(1h,3h)-二酮的多环衍生物及其药物组合物、其制备方法和其用途
WO2012008508A1 (ja) 複素環化合物
WO2019241467A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2025231260A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US20250312335A1 (en) Flt combination therapy for cancer and compositions therefor
HK1147994B (en) Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210629